Amman, Feb. 26 (Petra) -- Hikma Pharmaceuticals reported audited financial results for the year ending Dec. 31, 2025, recording 7% revenue increase (6% at constant currency) to $3.349 billion, up from $3.127 billion in 2024.
In a statement Thursday, the company attributed growth to its three geographic regions North America, the Middle East and North Africa, and Europe, driven by "strong" performance in branded medicines and "Hikma Rx", alongside improved performance in the generics segment.
Said Darwazah, Hikma CEO, said the "robust" momentum in branded medicines and Hikma Rx, combined with regional growth, enabled the group to increase both revenue and profits, in line with expectations while maintaining flexible margins.
He added that the company is taking measured steps to address challenges in the generics sector and remains "confident in its long-term" prospects, with 2026 guidance based on continued operational momentum and investment to support sustainable growth.
Hikma also announced a 5% increase in total dividend distributions and launched a share buyback program worth up to $250 million in 2026, reflecting a strong financial position and liquidity generation capability.
Additionally, the company expects group revenues to grow between 2%-4% in 2026.
//Petra// NQ
